<DOC>
	<DOCNO>NCT02105116</DOCNO>
	<brief_summary>This pilot clinical trial study cell donate close genetic relative help keep acute myeloid leukemia ( AML ) come back standard chemotherapy induces complete remission . Blood cell obtain donor include variety blood cell may trigger patient 's immune system react AML cell .</brief_summary>
	<brief_title>AML Therapy With Irradiated Allogeneic Cells</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Toxicity haploidentical allogeneic cellular therapy patient complete remission ( CR ) ( CR incomplete platelet recovery [ CRp ] ) induction chemotherapy fludarabine ( fludarabine phosphate ) -cytarabine . II . Efficacy haploidentical allogeneic cellular therapy patient CR ( CRp ) induction chemotherapy fludarabine-cytarabine ( remission rate 6 , 12 , 18 , 24 month ) . SECONDARY OBJECTIVES : I. Immunologic parameter haploidentical therapy : host anti-leukemia T cell ; host regulatory T cell . OUTLINE : INDUCTION CHEMOTHERAPY : Patients receive fludarabine phosphate intravenously ( IV ) 1 hour daily ( QD ) 5 day cytarabine IV 4 hour 5 day . Treatment may continue 1 2 course discretion treat physician . ALLOGENEIC CELLULAR THERAPY : Patients undergo irradiate donor lymphocyte infusion ( DLI ) 3 x 10^8 cluster differentiation ( CD ) 3+ cells/kg 8 week . Patients stable disease may repeat irradiated DLI every 8-12 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Histologically proven nonM3 AML : Refractory/relapsed AML OR Initial diagnosis AML patient &gt; = 60 year old Total bilirubin = &lt; 1.5 time upper limit normal ( ULN ) institutional limit ( unless Gilbert 's disease ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 X institutional ULN Cardiac leave ventricular ejection fraction ( LVEF ) &gt; = 35 % Serum creatinine = &lt; 1.5 mg/dl Any organ dysfunction think secondary disease consider separately patient include investigator discretion Patients must give informed consent Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 3 Must potential haploidentical donor ( parent , sibling , child ) A patient eligible second enrollment ( allocellular therapy ) follow inclusion criterion meet : Patient must document CR CRp 1 2 cycle fludarabine + cytarabine Patient must candidate allohematopoietic stem cell transplant ( HSCT ) Patient must partially ( &gt; = 3/6 class I antigen ) human leukocyte antigen ( HLA ) match ( serology low resolution deoxyribonucleic acid [ DNA ] test ) relative able serve donor Patients must active uncontrolled infection , medical psychological/social condition might increase likelihood patient adverse effect poor outcome Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) institutional limit ( unless Gilbert 's disease ) AST ( SGOT ) /ALT ( SGPT ) = &lt; 2.5 X institutional ULN Serum creatinine &lt; 2.0 mg/dl ECOG performance status = &lt; 2 DONOR : donor must relate patient partially ( &gt; = 3/6 antigen ) HLAmatched DONOR : donor must meet New Brunswick Affiliated Hospitals ( NBAH ) requirement hematopoietic stem cell donation , include : DONOR : age &gt; = 18 year old DONOR : white blood cell ( WBC ) 4.010.0 x 10^3/mm^3 DONOR : platelet count 150,000 440,000/mm^3 DONOR : hemoglobin/hematocrit ; 12.518 g/dl , 38 54 % DONOR : pregnant lactate DONOR : human immunodeficiency virus ( HIV ) 1 , HIV2 , hepatitis C virus ( HCV ) , hepatitis B core human Tlymphotropic virus ( HTLV ) I/II seropositive ; hepatitis B surface antigen ( HB S ag ) ( ) ; meet infectious disease screen criterion utilized NBAH Blood Center DONOR : uncontrolled infection , medical psychological/social condition , medication might increase likelihood patient donor adverse effect poor outcome DONOR : meet blood bank criterion blood product donation ( determine NBAH Blood Center screen history laboratory study ) History current prior medical problem investigator feel prevent administration therapy assessment response due excess toxicity Patients know active central nervous system ( CNS ) leukemia exclude clinical study Known HIVpositive patient exclude study Patients may pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>